Additional pathways, including non-alcoholic fatty liver disease (NAFLD), C-type lectin receptor signaling, prolactin signaling, estrogen signaling, and leishmaniasis, were also enriched. Here, CLEC4D is linked to metabolic dysfunction-associated steatotic liver disease.